Testicular germ cell tumors

Current Opinion in Oncology

Volumn 19, Issue 3, 2007, Pages 222-228

  Bridges, Benjamin ^a   Hussain, Arif ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Chemotherapy; Genetic studies; Germ cell tumor; Nonseminomatous germ cell tumor; Seminoma; Tumor marker

Indexed keywords

ARSENIC TRIOXIDE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; OXALIPLATIN; PACLITAXEL; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CRYPTORCHISM; EPIGENETICS; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GERM CELL TUMOR; HUMAN; MALE INFERTILITY; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEMINOMA; TESTIS TUMOR; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

GENE EXPRESSION PROFILING; GERMINOMA; HUMANS; MALE; RISK FACTORS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247171331     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3280ad43df     Document Type: Review

References (44)

1. Bray F, Richiardi L, Ekbom A, et al. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 2006; 118:3099-3111.
2. Jacobsen R, Moller H, Thoresen SO, et al. Trends in testicular cancer incidence in the Nordic countries, focusing on the recent decrease in Denmark. Int J Androl 2006; 29:199-204.
3. Walsh TJ, Grady RW, Porter MP, et al. Incidence of testicular germ cell cancers in U.S. children: SEER program experience 1973 to 2000. Urology 2006; 68:402-405; discussion 405. This report demonstrates that in contrast to adults, no increase in TGCT incidence has occurred in the US prepubertal population over the 27-year period from 1973 to 2000.
4. McGlynn KA, Graubard BI, Klebanoff MA, Longnecker MP. Risk factors for cryptorchism among populations at differing risks of testicular cancer. Int J Epidemiol 2006; 35:787-795.
5. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol 2005; 174:1819-1822.
6. Nistal M, Gonzalez-Peramato P, Regadera J, et al. Primary testicular lesions are associated with testicular germ cell tumors of adult men. Am J Surg Pathol 2006; 30:1260-1268.
7. Shankar S, Davies S, Giller R, et al. In utero exposure to female hormones and germ cell tumors in children. Cancer 2006; 106:1169-1177.
8. van Dijk MR, Steyerberg EW, Habbema JD. Survival of nonseminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur J Cancer 2006; 42:820-826.
9. Crockford GP, Linger R, Hockley S, et al. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet 2006; 15:443-451. Although the association between family history and TGCT risk is higher in this disease than many other cancers, to date no single susceptibility genetic locus has been shown to account for most of the familial cases of TGCTs. This updated study encompassing 237 kindreds further confirms that multiple weak susceptibility loci rather than a specific locus is likely contribute to TGCT pathogenesis.
10. Rapley EA, Crockford GP, Teare D, et al. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet 2000; 24:197-200.
11. Ewis AA, Lee J, Naroda T, et al. Lack of association between the incidence of testicular germ cell tumors and Y-chromosome haplogroups in the Japanese population. Int J Urol 2006; 13:1212-1217.
12. Nathanson KL, Kanetsky PA, Hawes R, et al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet 2005; 77:1034-1043.
13. Bianchi NO, Richard SM, Pavicic W. Y chromosome instability in testicular cancer. Mutat Res 2006; 612:172-188. An excellent review on Y chromosome structural abnormalities and potential role in male infertility and TGCTs.
14. Guan K, Nayernia K, Maier LS, et al. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 2006; 440:1199-1203. It is demonstrated for the first time that adult mouse testis spermatogonial stem cells, which maintain adult spermatogenesis, have the potential to acquire properties of embryonic stem cells, including the ability to differentiate into various organs. This has important implications for stem cell-related research.
15. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006; 124:1169-1181. An elegant study that identified two microRNAs, miR-372 and 373, which can abrogate wild type p53 function by inhibiting an inhibitor (LATS2) of cdk, allowing cells to overcome a G1S block and therefore proliferate. miR-372 and 373 are not only expressed in embryonic stem cells but also in TGCTs. Most TGCTs have wild type p53. The authors suggest that there is no selective advantage to mutate p53 in TGCTs since its function can be abrogated by miR-372 and 373.
16. Christoph F, Kempkensteffen C, Weikert S, et al. Frequent epigenetic inactivation of p53 target genes in seminomatous and nonseminomatous germ cell tumors. Cancer Lett 2007; 247:137-142.
17. Kempkensteffen C, Christoph F, Weikert S, et al. Epigenetic silencing of the putative tumor suppressor gene testisin in testicular germ cell tumors. J Cancer Res Clin Oncol 2006; 132:765-770.
18. Lind G, Skotheim R, Fraga M, et al. Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J Pathol 2006; 210:441-449.
19. Kawakami T, Zhang C, Okada Y, Okamoto K. Erasure of methylation imprint at the promoter and CTCF-binding site upstream of H19 in human testicular germ cell tumors of adolescents indicate their fetal germ cell origin. Oncogene 2006; 25:3225-3236. Similar to fetal germ cells, erasure of methylation in the promoter region of the H19 gene was demonstrated in TGCT specimens, while two primary testicular malignant lymphomas maintained the adult imprint.
20. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006; 367:754-765. A nice overview on the developments in TGCTs over the past decade.
21. Korkola JE, Houldsworth J, Chadalavada RS, et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006; 66:820-827. This study further characterizes genes associated with 12p gain in TGCTs. Coordinate overexpression of a gene cluster at 12p13.31 was observed in embryonal carcinomas and seminomas, while certain other stem cell-associated genes were overexpressed in the former relative to the latter. The authors suggest that differential expression of such core stem cell genes may account for the more pluripotent character of embryonal carcinomas compared with seminomas.
22. Looijenga LH, Hersmus R, Gillis AJ, et al. Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res 2006; 66:290-302. The primordial cell origin of classic seminoma vs. primary spermatocyte origin of spermatocytic seminoma is further demonstrated by expression profiling. In addition, DMRT1, a gene on chromosome 9, is implicated in spermatocytic seminoma.
23. Batistatou A, Scopa CD, Ravazoula P, et al. Involvement of dysadherin and E-cadherin in the development of testicular tumours. Br J Cancer 2005; 93:1382-1387.
24. Sonne SB, Hoei-Hansen CE, Nielsen JE, et al. CDH1 (E-cadherin) in testicular germ cell neoplasia: suppressed translation of mRNA in preinvasive carcinoma in situ but increased protein levels in advanced tumours. APMIS 2006; 114:549-558.
25. Brehm R, Ruttinger C, Fischer P, et al. Transition from preinvasive carcinoma in situ to seminoma is accompanied by a reduction of connexin 43 expression in Sertoli cells and germ cells. Neoplasia 2006; 8:499-509.
26. Mueller T, Mueller LP, Luetzkendorf J, et al. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol 2006; 27:71-83.
27. Spiess PE, Brown GA, Liu P, et al. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 2006; 107:1483-1490. By analyzing NSGCT patients with stage IIa-III disease who were treated with chemotherapy followed by RPLND, this study has attempted to identify factors that would predict their clinical outcomes. Although there are certain limitations to the study, including its retrospective analysis of patients treated with chemotherapy regimens that evolved over a 23-year period, and the limited numbers of patients who in fact had elevated tumor markers postchemotherapy but not prior to RPLND, this study does identify several prognostic factors that can be of potential use in the management of such patients if further validated.
28. Biermann K, Klingmuller D, Koch A, et al. Diagnostic value of markers M2A, OCT3/4, AP-2gamma, PLAP and c-KIT in the detection of extragonadal seminomas. Histopathology 2006; 49:290-297.
29. Lau SK, Chang KL. OCT4: a sensitive and specific immunohistochemical marker for metastatic germ cell tumors. Adv Anat Pathol 2006; 13:76-79.
30. Sung MT, Jones TD, Beck SD, et al. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. Hum Pathol 2006; 37:662-667.
31. Steiner H, Muller T, Gozzi C, et al. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours. BJU Int 2006; 98:349-352.
32. Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005; 23:9290-9294.
33. Fossa SD, Paluchowska B, Horwich A, et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer 2005; 93:1209-1214.
34. Bajorin DF, Nichols CR, Margolin KA, et al. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): a cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. J Clin Oncol, 2006 ASCO Annual Meeting Proc Part I 2006 24:4510.
35. Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 2006; 106:1217-1226.
36. Bedano PM, Brames MJ, Williams SD, et al. Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. J Clin Oncol 2006; 24:5403-5407.
37. Beer TM, Tangen CM, Nichols CR, et al. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 2006; 106:2624-2629.
38. Einhorn LH, Brames MJ, Heinrich MC, et al. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006; 29:12-13.
39. Carver BS, Bianco FJ Jr, Shayegan B, et al. Predicting teratoma in the retroperitoneum in men undergoing postchemotherapy retroperitoneal lymph node dissection. J Urol 2006; 176:100-103.
40. Ehrlich Y, Yossepowitch O, Kedar D, Baniel J. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection. BJU Int 2006; 97:1221-1224.
41. Geldart TR, Gale J, McKendrick J, et al. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int 2006; 98:353-358.
42. Oldenburg J, Alfsen GC, Waehre H, Fossa SD. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer 2006; 94:820-827.
43. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24:467-475.
44. Haugnes HS, Aass N, Fossa SD, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2006; 23 October [Epub ahead of print].